FDA approves Sarepta drug for muscular dystrophy with rare genetic mutation February 26, 2021 Auto Bot BioPharma, biopharma nl, Cambridge, Duchenne muscular dystrophy, FDA, Massachusetts, Pharma, Rare diseases, Sarepta Therapeutics 0 The FDA decision gives Sarepta Therapeutics its third approved drug for Duchenne muscular dystrophy. The accelerated approval requires the biotech to conduct additional clinical testing to confirm the drug’s benefit.